Eton Pharmaceuticals, Inc.
NASDAQ: ETON0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sean E. Brynjelsen
- Employees
- 44
- Headquarters
- Deer Park, United States
- IPO year
- 2018
- Market cap
- $930.8M
- Website
- https://www.etonpharma.com
Loading ETON…
Loading profile data…Frequently asked questions about ETON
What does Eton Pharmaceuticals, Inc. (ETON) do?
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease;...
Where does ETON trade?
Eton Pharmaceuticals, Inc. (ETON) trades on the NASDAQ.
What sector is ETON in?
Eton Pharmaceuticals, Inc. (ETON) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Eton Pharmaceuticals, Inc.?
Sean E. Brynjelsen is the chief executive officer of Eton Pharmaceuticals, Inc. (ETON).
Where is Eton Pharmaceuticals, Inc. headquartered?
Eton Pharmaceuticals, Inc. is headquartered in United States.
Does ETON pay a dividend?
Eton Pharmaceuticals, Inc. (ETON) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ETON go public?
Eton Pharmaceuticals, Inc. (ETON) completed its initial public offering in 2018.